CBP Loss Cooperates with PTEN Haploinsufficiency to Drive Prostate Cancer: Implications for Epigenetic Therapy

Liya Ding1,2,4, Shuai Chen6, Ping Liu6,10, Yunqian Pan1,2,4, Jian Zhong1,2,4, Kevin M. Regan2, Liguo Wang3, Chunrong Yu6, Anthony Rizzardi7, Liang Cheng9, Jun Zhang5, Stephen C. Schmechel7, John C. Cheville5, Jan Van Deursen1,4, Donald J. Tindall5,9, and Haojie Huang1,2,4

Introduction

Prostate cancer is the most commonly diagnosed malignancy and the second leading cause of cancer death in American men. Clinical prostate cancer is extremely rare in men younger than 45 years of age, with less than 1 in 10,000 occurrences. The incidence increases dramatically over the ensuing decades, with a 1 in 6 chance of cancer detection during the ages of 60–80. Intriguingly, autopsy studies demonstrate that high-grade prostatic intraepithelial neoplasia (PIN) and small/microscopic carcinomas are present in the prostate of up to 29% of men at 30 to 40 years of age (1). These findings indicate that PIN/low-grade cancers frequently develop in the prostate of adult men at an early age. It is of paramount importance to elucidate the genetic/epigenetic lesions responsible for early-stage pathogenesis in the prostate.

The tumor suppressor gene PTEN is frequently mutated, deleted, or expressed at reduced levels in human prostate cancer (2, 3). Loss of heterozygosity (LOH) in the PTEN locus occurs in up to 20% of localized but more than 60% of advanced/metastatic prostate cancer, suggesting that PTEN haploinsufficiency plays an important role in prostate cancer initiation and development into the advanced/aggressive stage. Mouse genetic studies show that Pt en heterozygous deletion alone fails to induce high-grade PIN until mice are older than 12 months (4, 5), suggesting that monoailelic loss of PTEN is insufficient to initiate prostate neoplasia and that cooperating oncogenic alterations are required.

CBP (CREB-binding protein, CREBBP) is a histone acetyltransferase that participates in many biologic processes, including cell growth, transformation, and organ development (6). Genome-wide analyses of histone modification show that histone acetylation generally correlates with gene activation (7), which is consistent with the finding that both mammalian and Drosophila CBP are involved in gene transcription by mediating histone H3 lysine 27 acetylation (H3K27Ac; refs. 8, 9). Gene inactivation mutations and chromosomal translocations with breakpoints at the CBP gene locus are frequently detected in different types of hematologic malignancies, including acute lymphoblastic leukemia.
leukemia and B-cell lymphoma (10, 11). Mouse genetic studies show that thymocyte-specific CBP deletion causes T-cell lymphoma (12). These findings imply that CBP functions as a hematologic tumor suppressor. Moreover, LOH at the CBP locus has been reported in human solid tumors and cancer cell lines, including PC-3 prostate cancer cells (13, 14). However, the relevance and the exact role of CBP in prostate cancer pathogenesis are not fully understood. In the present study, we demonstrate that reduced expression of CBP correlates with PTEN expression in a cohort of human prostate tumors. Concomitant deletion of Cbp and Pten induces early-life high-grade PIN/low-grade cancer. Treatment of Cbp/Pten compound-deficient mice with the histone deacetylase inhibitor panobinostat diminishes PIN lesions.

Materials and Methods

Generation of Cbp and Pten prostate-specific deletion mice

Cbp conditional knockout (Cbp<sup>fl/fl</sup>) mice were provided by Dr. Jan van Deursen at Mayo Clinic (12). Pten conditional knockout (Pten<sup>fl/fl</sup>) mice were originally generated in the laboratory of Dr. Hong Wu at University of California Los Angeles (Los Angeles, CA; ref. 15) and purchased from The Jackson Laboratory. Pb-Cre<sup>+</sup> transgenic mice generated in the laboratory of Dr. Pradip Roy-Burman at University of Southern California, Los Angeles, CA (16) were acquired from the National Cancer Institute (NCI) Mouse Repository. Cohorts of Cbp<sup>pc<sup>-/-</sup></sup>;Pten<sup>fl/fl</sup>, Cbp<sup>pc<sup>+</sup></sup>;Pten<sup>fl/fl</sup>, Cbp<sup>pc<sup>-/-</sup></sup> and Pten<sup>pc<sup>-/-</sup></sup> mice were generated from Cbp<sup>pc<sup>-/-</sup></sup>;Pten<sup>pc<sup>+</sup></sup> males and Cbp<sup>pc<sup>+</sup></sup>;Pten<sup>pc<sup>-/-</sup></sup> females, which were obtained by cross breeding Pb-Cre<sup>+</sup> males with Cbp<sup>pc<sup>+</sup></sup> and Pten<sup>pc<sup>-/-</sup></sup> females. All mice were maintained under standard conditions of feeding, light, and temperature with free access to food and water. All experimental protocols were approved by the Institutional Animal Care and Use Committee at Mayo Clinic.

PCR-based genotyping of mice

Genotyping of wild-type and conditional alleles of Cbp and Pten genes as well as the Cre transgene was performed according to previously described PCR protocols (12, 16, 17). Primer sequences are provided in Supplementary Table S1.

Cell lines, cell culture, and transfection

DU145 cell line was purchased from the American Type Culture Collection and cultured in RPMI-1640 (Invitrogen) supplemented with 10% FBS (Hyclone). LAPC-4 cell line was provided by Dr. Charles Sawyers (Memorial Sloan-Kettering Cancer Center, New York, NY) and cultured in Iscove’s Modified Eagle Medium (IMEM) with 10% FBS. Pten-positive and -negative MEFs were provided by Dr. Zhenbang Chen at Meharry Medical College (Nashville, TN; ref. 18) and cultured in Dulbecco’s Modified Eagle Medium with 10% FBS. These cell lines have been tested and authenticated (karyotyping, AR expression, and PTEN mutation status) for less than 6 months before the first submission of the manuscript. Cell transfection was performed by electroporation using an Electro Square Porator ECM 830 (BTX) as described previously (19).

Panobinostat (LBH589) treatment of mice

Six-month-old Cbp<sup>pc<sup>-/-</sup></sup>;Pten<sup>pc<sup>+</sup></sup> male mice were randomly assigned into two groups (n = 9/group) for treatment with vehicle or LBH589 (20 mg/kg/d) daily by intraperitoneal injection for 30 days. LBH589 was dissolved in 5% DMSO/PBS solution.

Human prostate cancer specimens, tissue microarray construction, and immunohistochemistry

Three intermediate-density prostate cancer TMAs were prepared by the Tissue and Cell Molecular Analysis Shared Resource at the Mayo Clinic Cancer Center. These TMAs contain cancers (Gleason sum 4–9) and tumor-adjacent benign tissues from the radical prostatectomy specimens of 78 patients with clinically localized prostate cancer (approximately four cores per case). All cases upon collection into the resource (approved by the Mayo Clinic Institutional Review Board) had repeat pathology characterization of tissues and review of medical records. IHC of TMA slides with antibodies for CBP, PTEN, and p27<sup>KIP1</sup> were performed as described in Supplementary Information. Digital images of IHC-stained TMA slides were obtained at ×40 magnification (0.0625 μm<sup>2</sup>/raw image pixel) using a whole slide scanner (ScanScope CS, Aperio).

Statistical Analysis

Cell culture experiments were carried out with three or more replicates. Statistical analyses were performed by the Student t test for cell culture and mouse tissue studies. The Fisher exact test (right tail) was used to measure the association of the expression of CBP, PTEN, and p27<sup>KIP1</sup> proteins in human prostate cancer specimens. P values of <0.05 are considered significant.

Additional methods

Additional methods are provided in Supplementary Information.

Results

Expression of CBP and PTEN protein correlates in human prostate cancer specimens

mRNA-based analysis shows that CBP expression appears to be lower in prostate cancers than in benign prostate hyperplasias (20). An independent IHC study demonstrates that the CBP protein is well expressed in both normal and malignant human prostate tissues (21). Notably, CBP expression is completely lost in a subset of primary tumors and lymph node metastases, but not in any benign prostate tissues examined (21). Because the previous findings regarding CBP expression in human prostate cancers are not entirely consistent, we employed TMA and IHC approaches to examine CBP protein expression in a cohort of human prostate cancers (n = 271 TMA specimens) and tumor-adjacent benign tissues (n = 25 TMA elements) obtained from 78 patients. IHC staining was evaluated on the basis of a semi-quantitative scale by considering both percentage of positive cells and staining intensity. We found that approximately 80% of benign tissues, but only about 45% of cancers expressed higher levels (staining index
we crossed proliferation and tumor formation CBP and PTEN act synergistically in prostate cell cohort of specimens (Fig. 1A, C, and D). common downstream target of them (see details below) in this adjacent benign tissues (Supplementary Fig. S2).

Expression of these proteins also correlates with p27KIP1, a correlation in 271 TMA prostate cancer specimens (Fig. 1B). Fisher exact test demonstrated whether the expression of CBP and PTEN protein low staining of CBP and PTEN are shown in the top and bottom panels of Fig. 1A, respectively. The Fisher exact test demonstrated that reduced expression of CBP and PTEN protein correlates in 271 TMA prostate cancer specimens (Fig. 1B). Expression of these proteins also correlates with p27KIP1, a common downstream target of them (see details below) in this cohort of specimens (Fig. 1A, C, and D).

CBP and PTEN act synergistically in prostate cell proliferation and tumor formation

To explore the role of CBP in prostate cancer pathogenesis, we crossed Cbp conditional (CbpLoxp/Loxp, hereafter termed as Cbpfl/fl) mice (12) with probasin (Pb)-Cre transgenic mice (Pb-Cre4) that express Cre recombinase in prostate epithelial cells (16). Effective deletion of the Cbp gene and protein was detected by PCR and immunofluorescent cytochemistry, respectively, in Pb-Cre4Cbpfl/fl (Cbppcpc/) and Pb-Cre4Cbpfl/fl (hereafter termed as Cbppppc/) mice (Supplementary Figs. S3A and S3B and S4A). Similar to the Cre-negative control mice, no signs of pathology were detected in all lobes of the prostate, including anterior prostate (AP), dorsolateral prostate (DLP), and ventral prostate (VP), in Cbppcpc/mice within 12 months of age (Fig. 2A and Supplementary Fig. S4B), indicating that cooperative oncogenic lesions are required. Because the TMA data showed that reduced expression of CBP and PTEN proteins correlates in human prostate cancer specimens (Fig. 1B), we sought to determine whether concomitant deletion of Cbp and Pten genes accelerates prostate cancer formation in mice. We established cohorts of Cbpfl/flPtenfl/fl (Cre-negative control), Cbppcpc/ and Cbppcpc/Ptenpcpc/ males by intercrossing Pb-Cre4, Cbpfl/fl and Ptenfl/fl (15) mice. PCR-based analysis demonstrated that the Cbp gene was almost completely deleted, but the Pten gene was only partially deleted in all the lobes of the prostates in Cbppcpc/Ptenpcpc/mice (Supplementary Fig. S3C). As early as 4 months of age, more than 80% of Cbppcpc/Ptenpcpc/mice (n = 11) exhibited clear histologic evidence of low-grade PIN (mouse PIN I and II) in all lobes, including AP, DLP, and VP (Supplementary Table S2). At 6 months of age, focal high-grade PIN (mouse PIN III and IV) in AP and DLP and low-grade PIN (mouse PIN II) in VP were detected in 100% penetrance in Cbppcpc/Ptenpcpc/mice examined (n = 20; Fig. 2A and Supplementary Fig. S4B; Supplementary Table S2). In contrast, no PIN was detected in the prostates of all Cbppcpc/littermates examined at this age (n = 15; Fig. 2A and Supplementary Table S2). Similar to the earlier reports that approximately 10% of Pten heterozygous mice develop PIN at an age younger than 9 months (4, 5), low-grade PIN was observed in only 1 of 12 Ptenpcpc/ males and no PIN was detected in the other 11 Ptenpcpc/ mice at 6 months of age.
pared with Cbp
Coregulation of p27KIP1 and DAB2IP expression by CBP in vivo

of parts (Fig. 2B and C), suggesting that combined inactivation of PTEN knockdown markedly decreased the expression of the exception of cyclin D1 (Fig. 3B). In contrast, CBP and/or PTEN either alone or in combination had little or no effect on expression of several key cell-cycle–driven proteins, including CDK1, CDK2, CDK6, and cyclin B1, with an exception of cyclin D1 (Fig. 3B). In contrast, CBP and/or PTEN knockdown markedly decreased the expression of the CDK inhibitors p27KIP1 and p21CIP1 and the growth-inhibitory protein DAB2IP, expression of which is often down-regulated in human prostate cancer (Fig. 3B; refs. 24, 25). CBP and/or PTEN knockdown also downregulated expression of p27KIP1, p21CIP1, and DAB2IP mRNAs in DU145 cells (Fig. 3C). Similar results were obtained in LAPC-4 cells (Supplementary Fig. S5A and B).

Next, we examined the impact of Cbp and Pten deletion on expression of p27KIP1, p21CIP1, and Dab2ip proteins in the mouse prostate. Nuclear expression of Cbp protein, nuclear, and cytoplasmic expression of Pten protein and no expression of phosphorylated Akt (Akt-p) was observed in prostate epithelial cells of Cbp<sup>L<sub>L</sub>;Pten<sup>W<sub>L</sub></sup></sub> control mice (Fig. 4A–D, left). As expected, Pten expression was reduced in the noncancerous prostate epithelium in Cbp<sup>p<sub>C</sub>−/−;Pten<sup>p<sub>C</sub>−/−</sub> mice (Fig. 4C, middle and D, left). P27<sup>KIP1</sup> and Dab2ip proteins were well expressed in both cytoplasm and nucleus in the normal prostate epithelium of control mice (Fig. 4E and F, left). Consistent with decreased expression of Cbp and Pten and increased expression of Akt-p, there were less cells expressing p27<sup>KIP1</sup> and Dab2ip proteins in PIN lesions in Cbp<sup>p<sub>C</sub>−/−;Pten<sup>p<sub>C</sub>−/−</sub> mice than in the normal prostates of control littermates (Fig. 4E and F, right). The specificity of the antibodies for p27<sup>KIP1</sup> and Dab2ip proteins

(Fig. 2A and Supplementary Table S2). No neoplastic changes were detected in any Cbp<sup>L<sub>L</sub>;Pten<sup>W<sub>L</sub></sup></sub> control mice (n = 16) (Fig. 2A and Supplementary Table S2). These histologic data indicate that loss of CBP cooperates with PTEN haploinsufficiency in prostate tumorigenesis. Accordingly, Ki-67 staining significantly increased in Cbp<sup>p<sub>C</sub>−/−;Pten<sup>p<sub>C</sub>−/−</sub> prostates compared with Cbp<sup>L<sub>L</sub>;Pten<sup>W<sub>L</sub></sup></sub>, Cbp<sup>p<sub>C</sub>−/−;Pten<sup>p<sub>C</sub>−/−</sub>, or Pten<sup>p<sub>C</sub>−/−</sup> counterparts (Fig. 2B and C), suggesting that combined inactivation of CBP and PTEN promotes prostate epithelial cell proliferation in vivo.

Coregulation of p27<sup>KIP1</sup> and DAB2IP expression by CBP and PTEN in vitro and in vivo

To explore the molecular mechanism underlying CBP/PTEN deletion-induced prostate cancer cell proliferation, we used small interfering RNAs (siRNA) to knock down endogenous CBP and PTEN individually or in combination in PTEN-positive human prostate cancer cell lines and measured the impact on cell-cycle control. Concomitant knockdown of CBP and PTEN increased proliferation of DU145 cells (Fig. 3A and B), although the effect was not as robust as in Cbp/Pten knockout mice (Fig. 2B and C). Knockdown of CBP and PTEN either alone or in combination had little or no effect on expression of several key cell-cycle–driven proteins, including CDK1, CDK2, CDK6, and cyclin B1, with an exception of cyclin D1 (Fig. 3B). In contrast, CBP and PTEN knockdown markedly decreased the expression of the

www.aacajournals.org

Cooperativity of CBP and PTEN Loss in Prostate Tumorigenesis

Figure 2. Concomitant deletion of two Cbp alleles and one Pten allele induces high-grade PIN and enhances prostatic epithelial cell proliferation. A, H&E of anterior (AP) and dorsolateral (DLP) prostates of 6-month-old Cbp<sup>L<sub>L</sub>;Pten<sup>W<sub>L</sub></sup></sub> (wild-type), Cbp<sup>p<sub>C</sub>−/−;Pten<sup>p<sub>C</sub>−/−</sub>, and Cbp<sup>p<sub>C</sub>−/−;Pten<sup>p<sub>C</sub>−/−</sub> mice. Scale bar, 50 μm. B and C, Ki-67 staining in each genotype are shown in C. Scale bar, 50 μm. *, P < 0.01.
were demonstrated by siRNA knockdown and IHC assays (Supplementary Fig. S6A and S6B). The IHC staining for Cbp, Pten, Akt-p, p27Kip1, and Dab2ip was quantified and the data are shown in Supplementary Fig. S7. Despite multiple efforts, we were unable to validate an antibody that can effectively detect p21Cip1 protein in mouse prostate sections by IHC. We conclude that knockdown or knockout of CBP and PTEN inhibits expression of p27KIP1, p21CIP1, and DAB2IP in human prostate cancer cells and p27Kip1 and Dab2ip expression in the mouse prostate. Moreover, p27KIP1 is a known tumor suppressor that is often downregulated in human prostate cancer (26). IHC staining and correlation studies showed that reduced expression of p27KIP1 correlates with CBP and PTEN expression in the cohort of 271 TMA specimens of human prostate cancer (Fig. 1A, C, and D). These data suggest that expression of p27KIP1 protein may also be regulated by CBP and/or PTEN in human prostate cancer.

CBP and PTEN regulation of H3K27Ac and H3K27me3 in human and mouse prostate cancer cells

CBP as a histone acetyltransferase responds for the “open” chromatin mark histone H3 lysine 27 acetylation (H3K27Ac) and gene activation in mammals and flies (8, 27, 28). In contrast, the histone methyltransferase EZH2 mediates the “close” chromatin mark H3 lysine 27 trimethylation (H3K27me3) and gene repression (29). It has been shown recently that CDK-dependent phosphorylation of EZH2 at threonine 350 (T350-p) is important for EZH2-mediated H3K27me3 and gene repression (19, 30, 31). Consistent with the report that PTEN inactivation increases CDK enzymatic activity and promotes cell-cycle progression (32), we found that Pten homozygous deletion in MEF or knockdown in DU145 human prostate cancer cells increases the overall levels of T350 (T345 in mouse) phosphorylated EZH2 and H3K27me3 levels (Fig. 5A and B). PTEN inactivation also increased total
EZH2 levels in both MEF and DU145 cells (Fig. 5A and B), which is consistent with early reports that EZH2 protein and mRNA are upregulated in prostate cancers in Nkx3.1+/+/Pten−/− and Cbp−/−/Pten−/− mice. Accordingly, CBP and PTEN knockdown alone or together resulted in concomitant upregulation of H3K27me3 and downregulation of H3K27Ac, an H3K27Ac-to-H3K27me3 switch in bulk histones in both DU145 and LAPC-4 cell lines (Fig. 5C–E and Supplementary Fig. S5A). Moreover, we recently identified Dab2ip, p27Kip1, and p21Cip1 as Ezh2 targets in mouse embryonic stem cells (35) and this finding was confirmed by ChIP-qPCR in DU145 cells (Supplementary Fig. S8). Consistent with the changes in the overall levels of H3K27Ac and H3K27me3 (Fig. 5C–E), codeloss of PTEN and CBP resulted in concomitant increase in H3K27me3 (except the p21Cip1 locus) and decrease in H3K27Ac at these gene loci in DU145 cells (Supplementary Fig. S9).

H3K27Ac levels were lower but H3K27me3 levels were much higher in PIN lesions in Cbp/Pten double knockout mice (Fig. 6A and B, right) compared with adjacent normal prostate epithelial cells in Cbp/Pten-deficient and wild-type control mice (Fig. 6A and B, middle and left). Accordingly, the levels of total and T345-phosphorylated Ezh2 were higher in Cbp/Pten double knockout PIN relative to adjacent normal prostate epithelium in both Cbp/Pten-deficient and wild-type control mice (Fig. 6C and D). Although total Ezh2 levels markedly increased (Fig. 6C), the level of serine 21 phosphorylation (S21-p), which inhibits EZH2’s H3K27me3 activity (36), was only modestly elevated in PIN compared with the adjacent noncancerous Cbp/Pten-deficient cells (Fig. 6E). The specificity of antibodies for EZH2, T350-p, S21-p, and H3K27me3 was demonstrated by siRNA knockdown and IHC assays (Supplementary Fig. S6C) or described previously.

Figure 4. Immunohistochemical analysis of protein expression in prostate sections of Cbp/Pten-deficient and "wild-type" mice. A, H&E of prostate sections of 6-month-old CbpL/L;PtenL/+ and Cbppc/C0/C0;Ptenpc/+ mice. Scale bar, 50 μm. Insets show high magnification images; scale bar, 10 μm. N, normal; PIN, prostatic intraepithelial neoplasia. B–F, immunohistochemical analysis of prostate sections of 6-month-old Cbp−/−;Pten−/− and Cbppc−/−;Pten−/− mice for expression of Cbp (B), Pten (C), Akt-p (serine 473 phosphorylation; D), p27Kip1 (E), and Dab2ip (F).
Moreover, LBH589 treatment induced nuclear condensa-

...Cbp and PTEN deficiency on expression of total and T350-phosphorylated EZH2, H3K27Ac and H3K27me3 levels on bulk histones. A, Western blot analysis of indicated proteins in Pten-proficient (−/−) and -deficient (−/−) MEFs. B, DU145 cells transfected as indicated for 48 hours followed by Western blot analysis. C–E, DU145 cells were transfected as indicated for 36 hours. Cytoplasmic (PTEN, ERK2) and nuclear (CBP, H3K27Ac, H3K27me3 and H3) extracts were prepared for Western blot (chemiluminescence-based) analysis of expression of indicated proteins (C). The relative expression of H3K27Ac and H3K27me3 was determined by normalizing to histone H3 first and then to the normalized value in siC-transfected cells and the quantitative data are shown in D and E, respectively. The experiments were repeated twice. Similar results were obtained from these experiments and the data shown was from one experiment.

The histone deacetylase inhibitor panobinostat reverses neoplastic growth in Cbp/Pten deletion prostates in mice

Because of the competitive nature of H3K27Ac and H3K27me3 modifications on the same lysine residue and the H3K27Ac-to-H3K27me3 switch induced by CBP and PTEN knockdown or knockout, we sought to determine whether the treatment of Cbp/Pten-deficient tumors with the histone deacetylase (HDAC) inhibitor would reverse the H3K27Ac-to-H3K27me3 ratio and induce tumor repression. Cinnamic acid hydroxamate panobinostat (LBH589) inhibits classes I and II HDACs (38) and is currently being tested in clinical trials for various malignancies, including prostate cancer (39, 40). We, therefore, measured the therapeutic effect of LBH589 on prostate tumor growth in Cbp<sup>−/−</sup>-Pten<sup>−/−</sup> mice. 6-month-old Cbp<sup>−/−</sup>-Pten<sup>−/−</sup> mice were randomly assigned for treatment with vehicle or LBH589 (20 mg/kg body weight; n = 9/group). We found that LBH589 not only inhibited disease progression, but also induced tumor regression by decreasing the incidence of PIN lesions in Cbp/Pten knockout mice (Fig. 7A). Moreover, LBH589 treatment induced nuclear condensa-

...phosphorylation (Akt-p) inhibition, increase in H3K27Ac, and decrease in H3K27me3 levels in the prostates of Cbp<sup>−/−</sup>-Pten<sup>−/−</sup> mice (Fig. 7B). It has been shown recently that treatment of chondrocytes with SAHA, another HDAC inhibitor, increased expression of PHLPP1, a known Akt phosphatase (41). Similarly, we found that LBH589 treatment of DU145 cells resulted in a moderate increase in PHLPP1 expression (Supplementary Fig. S11A). These data suggest that panobinostat-induced inhibition of Akt phosphorylation can be attributed, at least in part, to PHLPP1 upregulation although our data cannot rule out other mechanisms of panobinostat action on Akt.

Further ChIP analysis showed that LBH589 treatment increased an increase in H3K27Ac and decreased H3K27me3 levels on bulk histones in CBP/PTEN double knockdown DU145 cells (Fig. 7D). Ki-67 staining and terminal deoxynucleotidyl transferase–mediated dUTP nick end labeling (TUNEL) assays demonstrated that treatment with LBH589 decreased cell proliferation and increased apoptosis in the prostates of Cbp<sup>−/−</sup>-Pten<sup>−/−</sup> mice (Fig. 7E). The IHC staining for Akt-p, H3K27Ac, H3K27me3, Ki-67, and TUNEL staining was quantified and the data are shown in Supplementary Fig. S11C–S11G. The effect of LBH589 on apoptosis was further confirmed by its induction of changes.
in expression of genes involved in apoptotic signaling pathways, including downregulation of the antiapoptotic proteins XIAP and BCL-xL and cleavage of caspase-3 and PARP (Supplementary Fig. S12A–S12C). Thus, the HDAC inhibitor LBH589 induces regression of PIN lesions in Cbp–/–/–; Pten–/–/– mice via both inhibition of cell proliferation and induction of apoptosis.

Discussion

CBP is implicated in human cancers (10, 11), but its precise role in prostate oncogenesis remains elusive. For the first time, we provide in vivo evidence that Cbp deletion induces high-grade PIN/low-grade cancer in the mouse prostate in a Pten heterozygous background. We further demonstrate that reduced expression of CBP correlates with decreased expression of PTEN in a cohort of human prostate cancer specimens. Thus, we have established a clinically relevant mouse model that recapitulates the pathogenesis of early-stage prostate cancer.

Genome-wide analyses show that histone acetylation generally correlates with gene activation (7). CBP mediates H3K27Ac in mammals and flies (8, 9), whereas EZH2 promotes H3K27me3 (29). In line with the fact that H3K27Ac and H3K27me3 modifications occur on the same lysine, CBP antagonizes PcG protein-mediated gene silencing in Drosophila (8). We demonstrated for the first time in mammalian cells that codepletion of CBP and PTEN induces an H3K27Ac-to-H3K27me3 switch in bulk histones. This observation is substantiated by our finding that PTEN inactivation results in EZH2 activation by increasing expression of total and T350-phosphorylated EZH2 in MEF, human prostate cancer cell lines, and in the mouse prostate. These findings support a model (Fig. 7F) wherein deletion of CBP alone reduces H3K27Ac levels at EZH2 target gene loci and compromises their expression. Upregulation of EZH2 protein and function (via T350 phosphorylation) due to PTEN inactivation increases the level of the H3K27me3 histone mark, which further reduces or completely shuts off the expression of EZH2 target genes, thereby favoring tumor formation. This model is further validated by the observation that expression of EZH2 target genes is downregulated owing to CBP and/or PTEN codepletion. The coordinative effect of CBP loss and EZH2 activation on gene repression triggered by PTEN loss provides a plausible explanation as to why CBP deletion alone is insufficient to induce neoplastic changes in the prostate, given that inactivation mutations of CBP gene are frequently detected in human prostate cancer.
Figure 7. Histone deacetylase inhibitor panobinostat (LBH589) induces tumor repression, cell proliferation inhibition, and apoptosis in Cbp<sup>pc−/−</sup>;Pten<sup>pc−/−</sup> mice. A, 6-month-old Cbp<sup>pc−/−</sup>;Pten<sup>pc−/−</sup> mice (n = 9 per group) were sacrificed (column 1) or treated with vehicle or LBH589 (20 mg/kg/d) for 1 month and then sacrificed (columns 2 and 3). Prostate tissues were harvested, sectioned, and H&E stained. Sections with comparable acini numbers in each group were examined for PIN acini. The data were obtained in a blinded fashion. M, month. * P < 0.05. B, histologic and immunohistochemical analysis of Akt-p, H3K27Ac, and H3K27me3 in prostate sections of mice treated with vehicle or LBH589. Scale bar, 50 μm. Insets show high magnification images; scale bar, 10 μm. C, effect of LBH589 on H3K27Ac and H3K27me3 levels at the DAB2IP gene locus in PTEN/CBP knockdown DU145 cells. Cells were transfected with CBP and PTEN-specific siRNAs for 24 hours and treated with 20 nmol/L LBH589 for 24 hours followed by ChIP analysis with H3K27Ac and H3K27me3 antibodies. Enrichment of H3K27Ac and H3K27me3 was determined by ChIP-qPCR (n = 3). * P < 0.01. D, effect of LBH589 on expression of H3K27Ac and H3K27me3 of bulk histones in PTEN/CBP knockdown DU145 cells. Cells were transfected as in C for 24 hours, treated with LBH589 at different doses (5, 10, 20 nmol/L) for 24 hours followed by Western blot analysis. The density of H3K27Ac and H3K27me3 was determined by normalizing to H3 first and then to the normalized value in mock-treated cells. E, Ki-67 staining and TUNEL assay were performed on prostate sections obtained from mice used in experiments as described in A. Scale bar, 50 μm. Insets show high magnification images; scale bar, 10 μm. F, diagram deciphering the synergistic effect of CBP and PTEN codeciency on the H3K27Ac-to-H3K27me3 switch on chromatin and their impact on gene expression. Light purple circles represent nucleosomes.
recurrent lymphomas and small-cell lung cancers (10, 11, 42), it is possible that like in the prostate, CBP, a generic histone acetyltransferase (6) may act as a tumor suppressor in a context-dependent manner in those types of tissues.

Besides its overexpression in metastatic prostate cancer, EZH2 was found significantly upregulated in benign prostatic hyperplasia and primary prostate cancer (43). EZH2 overexpression in early lesions such as PIN is also observed in Pten-knockout mice (34). Thus, in addition to its role in late-stage castration-resistant prostate cancer (37), there is ample evidence suggesting that deregulated EZH2 also plays a pivotal role in the early-stage pathogenesis of prostate cancer. This notion is fully supported by our model wherein EZH2 is crucial for Cbp/Pten deletion-induced tumorigenesis in the prostate (Fig. 7F).

AKT is invariably activated in PTEN-null prostate cancer (15). Transgenic expression of constitutively active AKT alone induces PIN in the mouse prostate (44), suggesting that AKT activation itself is sufficient to drive prostate epithelial cell transformation and early-stage prostate cancer pathogenesis. The finding in mouse models is substantiated by the observation that AKT phosphorylation is significantly elevated at human PIN (45). Intriguingly, we found that Akt is highly phosphorylated in PIN, but not in the adjacent nonmalignant prostatic epithelial cells in Cbp<sup>fl/fl</sup>-Pten<sup>fl/fl</sup> mice and in the prostatic epithelium in "wild-type" mice. Thus, homozygous Cbp deletion in Pten heterozygous background predisposes the prostatic epithelium for secondary genetic and/or epigenetic lesions, which may in turn lead to Akt activation and prostate tumorigenesis. Further analysis is warranted to define the molecular basis underlying Akt activation in PIN lesions in Cbp/Pten compound-deficient mice.

An early study demonstrates that AKT phosphorylates EZH2 at S21 and inhibits EZH2's H3K27me3 activity (36). An independent study reports that T350 but not S21 phosphorylation was readily detected by mass spectrometry in 293T cells (30), suggesting that the overall level of S21 phosphorylation may be lower than T350 phosphorylation in these cells. Moreover, it has been shown recently that although both androgen-sensitive LNCaP and castration-resistant abl prostate cancer cells are PTEN-negative, surprisingly, EZH2 S21 phosphorylation was barely detected in LNCaP but was much higher in abl (37), implying that in addition to PTEN loss, other defects are essential for AKT-mediated S21 phosphorylation in prostate cancer cells. Indeed, besides PTEN loss, AKT is hyperactivated due to decreased expression of the AKT phosphatase PHLPP1 and the impaired FKBP51-PhLPP1 complex in abl cells under androgen depletion conditions (34, 37). In agreement with the findings from these studies, we found that although Akt was activated in PIN in non-castrated Cbp/Pten knockout mice (Fig. 4D), only very modest S21 phosphorylation of Ezh2 was detected in these tissues (Fig. 6E). In contrast, both total Ezh2 and T350 phosphorylation, an indicator of Ezh2 activation (19, 30, 31), was substantially upregulated (Fig. 6C and D), which is consistent with high levels of H3K27me3 in these tissues (Fig. 6B and Supplementary Fig. S10). Based upon the findings from our mouse model and others from human prostate cancers and cell lines (37), it can be postulated that S21 phosphorylation-mediated inhibitory effect on EZH2's H3K27me3 activity is minimal in uncastrated PTEN-deficient prostate tumors like those in Cbp/Pten deletion mice. In castration-resistant prostate cancer, however, the H3K27me3-dependent Polycomb function of EZH2 may be mitigated due to aberrant activation of AKT and subsequent S21 hyperphosphorylation of EZH2 (37).

A pilot phase I clinical study showed that the anticancer effect of oral panobinostat (LBH589) on castration-resistant prostate cancer was not quite promising, even though increased histone acetylation was observed in peripheral blood mononuclear cells (40), suggesting that new biomarkers are needed to identify patients with prostate cancer who are responsive to HDAC inhibitors. Inactivation mutations in the Cbp gene frequently recur in relapsed lymphoblastic leukemia and B-cell lymphoma (10, 11) and that Cbp deletion induces T-cell lymphoma in mice (12). Notably, patients with lymphoma respond favorably to the HDAC inhibitor. In a striking similarity, we demonstrated that both CBP and PTEN protein expression is downregulated in a large cohort of human prostate cancer samples and that LBH589 treatment induces regression of Cbp/Pten-deficient PIN in mice. Our findings suggest that CBP- and PTEN-deficient prostate cancer patients may be susceptible to the HDAC inhibitory drugs (Fig. 7F).

In summary, we demonstrate that concomitant deletion of two Cbp alleles and one Pten allele induces early-life high-grade PIN/low-grade cancer in the mouse prostate. Of note, whether PTEN is lost in human PIN lesions has recently been called into question (46), suggesting a potential weakness in our model. Nonetheless, we further show that codeficiency of CBP and PTEN increases cell proliferation, induces an acetylation-to-trimethylation shift on lysine 27 of pan histone H3, and causes transcriptional repression of DAB2IP and p27<sup>KIP1</sup> tumor suppressor proteins of EZH2 targets. Our model not only recapitulates the pathogenesis of early-stage prostate cancer, but also is highly clinically relevant as expression of CBP, PTEN, and p27<sup>KIP1</sup> correlates in human prostate cancer. Our finding that treatment of Cbp<sup>p<sup>pc</sup></sup>-/+;Pten<sup>pc</sup>-/+ mice with panobinostat induces regression of PIN implies that deregulated CBP and PTEN may serve as a biomarker for epigenetic-targeted therapy of human prostate cancers.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors' Contributions
Conception and design: L. Ding, S. Chen, J. Van Deursen, H. Huang
Development of methodology: L. Ding, S. Chen, P. Liu, A. Rizzardi, S.C. Schmechel, J. Van Deursen
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): L. Ding, S. Chen, J. Zhong, K.M. Regan, A. Rizzardi, L. Cheng, S.C. Schmechel, J.C. Cheville
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): L. Ding, P. Liu, L. Wang, A. Rizzardi, L. Cheng, J. Zhang, J. Van Deursen, H. Huang
Writing, review, and/or revision of the manuscript: L. Ding, S. Chen, J. Zhong, A. Rizzardi, L. Cheng, S.C. Schmechel, J.C. Cheville, J. Van Deursen, D.J. Tindall, H. Huang
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): L. Ding, S. Chen, Y. Pan, C. Yu, A. Rizzardi, L. Cheng
Study supervision: C. Yu, J. Zhang, H. Huang

www.aacrjournals.org Cancer Res; 74(7) April 1, 2014

2059

Published OnlineFirst February 3, 2014; DOI: 10.1158/0008-5472.CAN-13-1659

Downloaded from cancerres.aacrjournals.org on April 20, 2017. © 2014 American Association for Cancer Research.
Grant Support

This work is supported in part by grants from the NIH (CA134514 and CA13996 to H. Huang; CA09516 to D. Tindall), the Department of Defense (W81XWH-09-1-622 and W81XWH-07-1-0137 to H. Huang) and the T.J. Martell Foundation.

References


CBP Loss Cooperates with PTEN Haploinsufficiency to Drive Prostate Cancer: Implications for Epigenetic Therapy

Liya Ding, Shuai Chen, Ping Liu, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-13-1659

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2014/02/05/0008-5472.CAN-13-1659.DC1

Cited articles
This article cites 46 articles, 22 of which you can access for free at:
http://cancerres.aacrjournals.org/content/74/7/2050.full.html#ref-list-1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.